AI-enabled solutions that provide advanced insights based on radiology images

Pixel for radiology

Solution specifically designed for oncologists to efficiently monitor disease progression

• Automated quantification: Segments and measures lesions of interest, providing accurate contours and long axis and short axis measurements¹

• Automated tracking: Links lesions across time points to create longitudinal tracking reports to automatically calculate lesion response

• Automated reporting: Automates therapy response criteria (like RECIST) and generates a comprehensive report that can be linked to the patient record in the EMR or in Tempus Hub

Pixel for oncology

Solution specifically designed to optimize how radiologists read images, detect findings, generate reports, and share insights with referring physicians

• Automated image analysis: One-click segmentation of lesions on CT and MR images¹

• Automated reporting: Report generated based on AI analysis that can be configured and customized for a more efficient workflow. Equips providers with advanced insights and editable reports based on radiology images, helping to reduce turnaround time and improve reporting consistency

• Seamless integration: Easily integrates AI-enabled tools with existing PACS, EHR, worklist, notification, and dictation systems to optimize workflows

Our impact

Pixel can be leveraged for multiple use cases across the care continuum.

References

1. One-click lesion segmentation is automated using DeepLook Precise (K202084) and is FDA-cleared but is not available for clinical use in the EU. DeepLook is the manufacturer of DeepLook Precise.
2. In the U.S., Tempus Pixel Lung is FDA-cleared (K203744) but is not indicated for lung nodule detection. Arterys Inc is the manufacturer of Tempus Pixel Lung, excluding any third party components described in this list. Lung nodule automated detection and quantification is powered by InferRead CT (K192880) where Infervision is the manufacturer of InferRead CT.
3. In the EU, Tempus Pixel Lung is CE-marked for detection and quantification of nodules. Arterys Inc is the manufacturer of Tempus Pixel Lung.
4. Kozuka T, Matsukubo Y, Kadoba T, et al. Efficiency of a computer-aided diagnosis (CAD) system with deep learning in detection of pulmonary nodules on 1-mm-thick images of computed tomography. Jpn J Radiol. 2020;38(11):1052-1061. https://doi.org/10.1007/s11604-020-01009-0.
5. Conant EF, Toledano AY, Periaswamy S, et al. Improving accuracy and efficiency with concurrent use of artificial intelligence for digital breast tomosynthesis. Radiology: Artificial Intelligence. 2019;1(4):e180096. https://doi.org/10.1148/ryai.2019180096.
6. Tempus Pixel Breast is FDA cleared (K203744) and CE marked; detection of lesions suspected of breast cancer is powered by iCAD’s ProFound AI (K203822). Arterys Inc is the manufacturer of Tempus Pixel Breast, excluding any third party components described in this list. iCAD is the manufacturer of ProFound AI.
7. Tempus Pixel Cardio is FDA-cleared (K203744). Arterys Inc is the manufacturer of Tempus Pixel Cardio.
8. Atkins MB. Integration of 4D-Flow into routine clinical practice of congenital and non-congenital cardiac MRI-18 months experience demonstrating decreased scan times, physician monitoring, and patient breath hold times. [366897]. CMR 2018; pp. 789-790.
9. Narang A, Miller T, Ameyaw K, et al. A machine learning algorithm for determination of left ventricle volumes and function: comparison to manual quantification. J Am Coll Cardiol. 2019;73(9):1638. Doi: https://www.jacc.org/doi/full/10.1016/S0735-1097%2819%2932244-2.
10. Tempus Pixel is FDA-cleared (K203744) and CE Marked. Prostate gland segmentation is powered by Quibim’s QP-Prostate® (K203582). QC against PI-RADS v2.1 guidelines is powered by Quibim’s QP-Prostate® (K203582) and QP-Prostate® CAD (K242683). Lesion detection and risk classification for clinically significant prostate cancer is powered by Quibim’s QP-Prostate® CAD (K242683). Arterys Inc is the manufacturer of Tempus Pixel. Quibim is the manufacturer of QP-Prostate® and QP-Prostate® CAD
11. Quibim data on file. J. Hillis and S. Mercaldo, “Quibim QP-Prostate CAD: Standalone Model Performance Assessment and Clinical Reader Performance Assessment: Clinical Study Report (Clinical  Reader),” Mass General Brigham, QUI-C-002-REP-002, 2024.